FDA
2nd June 2020

FDA Announces New Changes to Permitted Marketing Status of OTC Monograph Drugs

In a recent webinar hosted by the FDA, Dr. Theresa M. Michele, director of the Office of Nonprescription Drugs at CDER, revealed a significant update on the generally recognized as safe and effective (GRASE) status of hundreds of Monograph ingredients.

FDA Announces New Changes to Permitted Marketing Status of OTC Monograph Drugs

Although the announcement for OTC Monograph user fees is pending, the FDA is actively working to clarify the new regulations for non-prescription products. As previously explained, the enactment of the CARES Act on March 27th included several additions to the Monograph Drug Review process, such as the OTC Monograph User Fee program (OMUFA), as well as changes to the permitted marketing of OTC drugs.

In a recent webinar hosted by the FDA, Dr. Theresa M. Michele, director of the Office of Nonprescription Drugs at CDER, revealed a significant update on the generally recognized as safe and effective (GRASE) status of hundreds of Monograph ingredients. The FDA has deemed 21 CFR 310.545 as a final administrative order – meaning that all active ingredients included under this part are not GRASE for the listed therapeutic indications.

The active ingredients under this part vary in classification and therefore, the impact on product marketing changes is dependent on the current Category according to existing monographs.

An OTC product can remain on the market if it:

  • Conforms to an existing final monograph or is Category I under a tentative final monograph (TFM).
  • Category I under advanced notice of proposed rulemaking (ANPR) and/or Category III under TFM.

An OTC product must be removed from market by September 23, 2020 if it contains any Category II drug.

To avoid being deemed misbranded, manufacturers of Category II drug products are required to undergo reformulation to fit the approved specifications discussed above, or succumb to the cumbersome NDA process.

In addition, manufacturers of any Monograph drug will be deemed misbranded if they fail to pay OMUFA fees within 45 days of fee publication.

With all the reform and modernization happening at FDA, it becomes increasingly important for OTC Monograph drug marketers to stay ahead of deadlines. ISS has decades of experience in handling regulatory interactions with the FDA on behalf of clients. Our scientific and regulatory experts are highly skilled at OTC product formulation, CMC and quality review, labeling, preparing for FDA meetings, and other regulatory interactions. Let ISS assist you in navigating the complex regulatory arena of OTC Monograph Review now!

Subscribe today and stay tuned for the latest Monograph Reform Developments from ISS. For custom advice on how ISS can help you, contact info@innovativescience.net

SUBSCRIBE HERE !

  • This field is for validation purposes and should be left unchanged.

Recent Related Articles

Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission
01 July 2020
Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission

Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more

Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices
25 June 2020
Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices

FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more

NDA vs. OTC Monograph: Which Pathway is Right for You?
22 June 2020
NDA vs. OTC Monograph: Which Pathway is Right for You?

One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more

4 Problems Importing Rapid Antibody Tests for Coronavirus
19 June 2020
4 Problems Importing Rapid Antibody Tests for Coronavirus

US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more

Let’s work together

The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today

Contact us